Ruxolitinib cream effectively managed mild to moderate pediatric AD, achieving significant disease control over 52 weeks with both 0.75% and 1.5% strengths. The study showed substantial lesion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results